Biopharmaceutical Venture Capital Trends: Coronavirus Disease (COVID-19) Company Impact Report

Biopharmaceutical Venture Capital Trends: Coronavirus Disease (COVID-19) Company Impact Report

Summary

This report examines the impact of the COVID-19 pandemic on venture capital deals for biopharmaceutical companies. This analysis is critical to understanding how the outbreak of COVID-19 impacted investments and how those VC deal trends may impact current and future venture capital investments.

Scope

This report is required reading for -

Investors that want to understand how COVID-19 has impacted VC deals in the biopharmaceutical industry as well as identifying companies that may be due for a round of financing in upcoming months
Companies that are due to raise venture capital in the near future and need to consider 2020 VC trends into their capital raising strategies.
Large pharma companies with investment groups or BD teams looking for partnership opportunities where companies may be in need of financing with changing VC trends during the COVID-19 pandemic.

Reasons to Buy

Monthly trends of VC deals by value and volume; including an analysis of monthly VC activity in China versus U.S. during the spread of the diease
Analyzes how COVID-19 has shifted investment trends by deal value, round, and therapeutic area
Assessment of investors activity level in biopharmaceutical VC deals prior to and during the COVID-19 pandemic
Identify biopharmaceutical companies that may be looking for rounds of financing and how they may be impacted by the shifted trends in VC investment

1 Executive Summary

2 Table of Contents

3 Venture Capital Trends

4 Investors in Biopharmas

5 Regional Breakout

6 Companies with Venture Capital at Risk

7 Key Findings

8 Appendix

List of Tables
Table 1: Q1 2020: Top Companies by Venture Capital Amount
Table 2: Top Therapeutic Areas Receiving Venture Capital (2020)
Table 3: Most Active Investors by Deal Volume: Q1 2020
Table 4: Most Active Investors by Deal Value: Q1 2020
Table 5: 2019: Top Investors by Deal Count
Table 6: 2019 VC Invested by Region (by Recipient HQ Location)
Table 7: Companies Actively Looking to Close Venture Capital Rounds
Table 8: Biopharma Companies with Planned Series A Financing
Table 9: Sample of Biopharma Companies with Expected Series B Financing
Table 10: Sample of Biopharma Companies with Expected Series C Financing
Table 11: Sample of Biopharma Companies with Expected Series D Financing

List of Figures
Figure 1: Venture Capital Deals by Month
Figure 2: Venture Capital Deal Value 2019 FY vs. 2020 ($M)
Figure 3: Deal Volume by Series
Figure 4: Deal Value by Series
Figure 5: VC for Infectious Diseases Drugs Table
Figure 6: Top Investors by Deal Count - Q1 2020 vs. 2019
Figure 7: Spread of COVID-19
Figure 8: Venture Capital Deals in China
Figure 9: Venture Capital Deals in the US